BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Immunocore reports first quarter financial results and provides a business update

  May 7, 2025

   · 

  25 min read
• Press Releases

  Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025

  May 7, 2025

   · 

  2 min read
• Press Releases

  Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

  May 7, 2025

   · 

  13 min read
• Press Releases

  Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients

  May 7, 2025

   · 

  11 min read
• Press Releases

  Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

  May 7, 2025

   · 

  50 min read
• Press Releases

  Family Heart Foundation Announces Results of Real-World Study in 273,770 Individuals with Cardiovascular Disease Demonstrating that Risk of Subsequent Cardiovascular Event Increases with Rising Lipoprotein(a) Levels

  May 7, 2025

   · 

  5 min read
• Press Releases

  Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies

  May 7, 2025

   · 

  3 min read
• Press Releases

  Ironwood Pharmaceuticals Reports First Quarter 2025 Results

  May 7, 2025

   · 

  19 min read
• Press Releases

  VectorY Therapeutics to Present Preclinical Data on Novel ALS Therapeutic Strategy at Target ALS Conference in Boston

  May 7, 2025

   · 

  3 min read
• Press Releases

  ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

  May 7, 2025

   · 

  19 min read